Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

In vitro cytotoxicity evaluation of thiourea derivatives bearing Salix sp. constituent against HK-1 cell lines.

Nordin NA, Lawai V, Ngaini Z, Abd Halim AN, Hwang SS, Linton RE, Lee BK, Neilsen PM.

Nat Prod Res. 2018 Dec 3:1-10. doi: 10.1080/14786419.2018.1517120. [Epub ahead of print]

PMID:
30507306
2.

Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer.

Shakya R, Tarulli GA, Sheng L, Lokman NA, Ricciardelli C, Pishas KI, Selinger CI, Kohonen-Corish MRJ, Cooper WA, Turner AG, Neilsen PM, Callen DF.

Oncogene. 2017 Aug;36(31):4469-4480. doi: 10.1038/onc.2017.66. Epub 2017 Apr 3.

PMID:
28368395
3.

Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells.

Pfister NT, Fomin V, Regunath K, Zhou JY, Zhou W, Silwal-Pandit L, Freed-Pastor WA, Laptenko O, Neo SP, Bargonetti J, Hoque M, Tian B, Gunaratne J, Engebraaten O, Manley JL, Børresen-Dale AL, Neilsen PM, Prives C.

Genes Dev. 2015 Jun 15;29(12):1298-315. doi: 10.1101/gad.263202.115. Epub 2015 Jun 16.

4.

p53 Represses the Oncogenic Sno-MiR-28 Derived from a SnoRNA.

Yu F, Bracken CP, Pillman KA, Lawrence DM, Goodall GJ, Callen DF, Neilsen PM.

PLoS One. 2015 Jun 10;10(6):e0129190. doi: 10.1371/journal.pone.0129190. eCollection 2015.

5.

Ankrd11 is a chromatin regulator involved in autism that is essential for neural development.

Gallagher D, Voronova A, Zander MA, Cancino GI, Bramall A, Krause MP, Abad C, Tekin M, Neilsen PM, Callen DF, Scherer SW, Keller GM, Kaplan DR, Walz K, Miller FD.

Dev Cell. 2015 Jan 12;32(1):31-42. doi: 10.1016/j.devcel.2014.11.031. Epub 2014 Dec 31.

6.

Ankrd11 is a chromatin regulator involved in autism that is essential for neural development.

Voronova A, Gallagher D, Zander M, Cancino G, Bramall A, Krause MP, Abad C, Tekin M, Neilsen PM, Callen DF, Scherer SW, Keller GM, Kaplan DR, Walz K, Miller FD.

Springerplus. 2015 Jun 12;4(Suppl 1):L28. doi: 10.1186/2193-1801-4-S1-L28. eCollection 2015. No abstract available.

7.

Characterization of ANKRD11 mutations in humans and mice related to KBG syndrome.

Walz K, Cohen D, Neilsen PM, Foster J 2nd, Brancati F, Demir K, Fisher R, Moffat M, Verbeek NE, Bjørgo K, Lo Castro A, Curatolo P, Novelli G, Abad C, Lei C, Zhang L, Diaz-Horta O, Young JI, Callen DF, Tekin M.

Hum Genet. 2015 Feb;134(2):181-90. doi: 10.1007/s00439-014-1509-2. Epub 2014 Nov 21.

PMID:
25413698
8.

Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling.

Pishas KI, Neuhaus SJ, Clayer MT, Schreiber AW, Lawrence DM, Perugini M, Whitfield RJ, Farshid G, Manavis J, Chryssidis S, Mayo BJ, Haycox RC, Ho K, Brown MP, D'Andrea RJ, Evdokiou A, Thomas DM, Desai J, Callen DF, Neilsen PM.

Cancer Res. 2014 Feb 1;74(3):921-31. doi: 10.1158/0008-5472.CAN-13-2424. Epub 2013 Dec 13.

9.

TAp63 regulates oncogenic miR-155 to mediate migration and tumour growth.

Mattiske S, Ho K, Noll JE, Neilsen PM, Callen DF, Suetani RJ.

Oncotarget. 2013 Nov;4(11):1894-903.

10.

A template-based approach to inhibitors of calpain 2, 20S proteasome, and HIV-1 protease.

Jones SA, Neilsen PM, Siew L, Callen DF, Goldfarb NE, Dunn BM, Abell AD.

ChemMedChem. 2013 Dec;8(12):1918-21. doi: 10.1002/cmdc.201300387. Epub 2013 Oct 15.

PMID:
24130198
11.

Pre-activation of the p53 pathway through Nutlin-3a sensitises sarcomas to drozitumab therapy.

Pishas KI, Neuhaus SJ, Clayer MT, Adwal A, Brown MP, Evdokiou A, Callen DF, Neilsen PM.

Oncol Rep. 2013 Jul;30(1):471-7. doi: 10.3892/or.2013.2454. Epub 2013 May 13.

PMID:
23670273
12.

Synthesis and extended activity of triazole-containing macrocyclic protease inhibitors.

Pehere AD, Pietsch M, Gütschow M, Neilsen PM, Pedersen DS, Nguyen S, Zvarec O, Sykes MJ, Callen DF, Abell AD.

Chemistry. 2013 Jun 10;19(24):7975-81. doi: 10.1002/chem.201204260. Epub 2013 Apr 18.

PMID:
23606616
13.

Development of a novel cell-based assay system EPISSAY for screening epigenetic drugs and liposome formulated decitabine.

Lim SP, Kumar R, Akkamsetty Y, Wang W, Ho K, Neilsen PM, Walther DJ, Suetani RJ, Prestidge C, Callen DF.

BMC Cancer. 2013 Mar 13;13:113. doi: 10.1186/1471-2407-13-113.

14.

Stimulating p53 down-under: a report from the 1st Australian p53 Workshop.

Neilsen PM, Braithwaite AW, Gamell C, Haupt S, Janic A, Strasser A, Wolyniec K, Haupt Y.

Cell Death Differ. 2013 Dec;20(12):1753-6. doi: 10.1038/cdd.2013.2. Epub 2013 Feb 1. No abstract available.

15.

Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9.

Chee JL, Saidin S, Lane DP, Leong SM, Noll JE, Neilsen PM, Phua YT, Gabra H, Lim TM.

Cell Cycle. 2013 Jan 15;12(2):278-88. doi: 10.4161/cc.23054. Epub 2012 Jan 15.

16.

New 26S proteasome inhibitors with high selectivity for chymotrypsin-like activity and p53-dependent cytotoxicity.

Neilsen PM, Pehere AD, Pishas KI, Callen DF, Abell AD.

ACS Chem Biol. 2013 Feb 15;8(2):353-9. doi: 10.1021/cb300549d. Epub 2012 Nov 28.

PMID:
23190346
17.

Mutant p53 drives invasion in breast tumors through up-regulation of miR-155.

Neilsen PM, Noll JE, Mattiske S, Bracken CP, Gregory PA, Schulz RB, Lim SP, Kumar R, Suetani RJ, Goodall GJ, Callen DF.

Oncogene. 2013 Jun 13;32(24):2992-3000. doi: 10.1038/onc.2012.305. Epub 2012 Jul 16.

PMID:
22797073
18.

A comparison of vitamin D activity in paired non-malignant and malignant human breast tissues.

Suetani RJ, Ho K, Jindal S, Manavis J, Neilsen PM, Pishas KI, Rippy E, Bochner M, Kollias J, Gill PG, Morris HA, Callen DF.

Mol Cell Endocrinol. 2012 Oct 15;362(1-2):202-10. doi: 10.1016/j.mce.2012.06.022. Epub 2012 Jun 29.

PMID:
22750718
19.

The oncogenic role of miR-155 in breast cancer.

Mattiske S, Suetani RJ, Neilsen PM, Callen DF.

Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1236-43. doi: 10.1158/1055-9965.EPI-12-0173. Epub 2012 Jun 26. Review.

20.

Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion.

Muller PA, Trinidad AG, Timpson P, Morton JP, Zanivan S, van den Berghe PV, Nixon C, Karim SA, Caswell PT, Noll JE, Coffill CR, Lane DP, Sansom OJ, Neilsen PM, Norman JC, Vousden KH.

Oncogene. 2013 Mar 7;32(10):1252-65. doi: 10.1038/onc.2012.148. Epub 2012 May 14.

21.

Specific-site methylation of tumour suppressor ANKRD11 in breast cancer.

Lim SP, Wong NC, Suetani RJ, Ho K, Ng JL, Neilsen PM, Gill PG, Kumar R, Callen DF.

Eur J Cancer. 2012 Nov;48(17):3300-9. doi: 10.1016/j.ejca.2012.03.023. Epub 2012 Apr 24.

PMID:
22538187
22.

Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome.

Neilsen PM, Noll JE, Suetani RJ, Schulz RB, Al-Ejeh F, Evdokiou A, Lane DP, Callen DF.

Oncotarget. 2011 Dec;2(12):1203-17.

23.

Inhibition of DNA-dependent protein kinase induces accelerated senescence in irradiated human cancer cells.

Azad A, Jackson S, Cullinane C, Natoli A, Neilsen PM, Callen DF, Maira SM, Hackl W, McArthur GA, Solomon B.

Mol Cancer Res. 2011 Dec;9(12):1696-707. doi: 10.1158/1541-7786.MCR-11-0312. Epub 2011 Oct 18.

24.

Mutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11.

Noll JE, Jeffery J, Al-Ejeh F, Kumar R, Khanna KK, Callen DF, Neilsen PM.

Oncogene. 2012 Jun 7;31(23):2836-48. doi: 10.1038/onc.2011.456. Epub 2011 Oct 10.

PMID:
21986947
25.

Genome-wide mapping of ZNF652 promoter binding sites in breast cancer cells.

Kumar R, Selth LA, Schulz RB, Tay BS, Neilsen PM, Callen DF.

J Cell Biochem. 2011 Oct;112(10):2742-7. doi: 10.1002/jcb.23214.

PMID:
21678463
26.

Targeting the p53 Pathway in Ewing Sarcoma.

Neilsen PM, Pishas KI, Callen DF, Thomas DM.

Sarcoma. 2011;2011:746939. doi: 10.1155/2011/746939. Epub 2010 Dec 9.

27.

Nutlin-3a is a potential therapeutic for ewing sarcoma.

Pishas KI, Al-Ejeh F, Zinonos I, Kumar R, Evdokiou A, Brown MP, Callen DF, Neilsen PM.

Clin Cancer Res. 2011 Feb 1;17(3):494-504. doi: 10.1158/1078-0432.CCR-10-1587. Epub 2010 Nov 23.

28.

Systematic characterisation of the rat and human CYP24A1 promoter.

Kumar R, Iachini DN, Neilsen PM, Kaplan J, Michalakas J, Anderson PH, May BK, Morris HA, Callen DF.

Mol Cell Endocrinol. 2010 Aug 30;325(1-2):46-53. doi: 10.1016/j.mce.2010.04.023. Epub 2010 May 5.

PMID:
20450955
29.

Co-expression of the androgen receptor and the transcription factor ZNF652 is related to prostate cancer outcome.

Callen DF, Ricciardelli C, Butler M, Stapleton A, Stahl J, Kench JG, Horsfall DJ, Tilley WD, Schulz R, Nesland JM, Neilsen PM, Kumar R, Holm R.

Oncol Rep. 2010 Apr;23(4):1045-52.

PMID:
20204290
30.

CBFA2T3-ZNF651, like CBFA2T3-ZNF652, functions as a transcriptional corepressor complex.

Kumar R, Cheney KM, Neilsen PM, Schulz RB, Callen DF.

FEBS Lett. 2010 Mar 5;584(5):859-64. doi: 10.1016/j.febslet.2010.01.047. Epub 2010 Jan 30.

31.

Identification of ANKRD11 as a p53 coactivator.

Neilsen PM, Cheney KM, Li CW, Chen JD, Cawrse JE, Schulz RB, Powell JA, Kumar R, Callen DF.

J Cell Sci. 2008 Nov 1;121(Pt 21):3541-52. doi: 10.1242/jcs.026351. Epub 2008 Oct 7.

32.

CBFA2T3-ZNF652 corepressor complex regulates transcription of the E-box gene HEB.

Kumar R, Cheney KM, McKirdy R, Neilsen PM, Schulz RB, Lee J, Cohen J, Booker GW, Callen DF.

J Biol Chem. 2008 Jul 4;283(27):19026-38. doi: 10.1074/jbc.M709136200. Epub 2008 May 2.

33.

FBXO31 is the chromosome 16q24.3 senescence gene, a candidate breast tumor suppressor, and a component of an SCF complex.

Kumar R, Neilsen PM, Crawford J, McKirdy R, Lee J, Powell JA, Saif Z, Martin JM, Lombaerts M, Cornelisse CJ, Cleton-Jansen AM, Callen DF.

Cancer Res. 2005 Dec 15;65(24):11304-13.

Supplemental Content

Loading ...
Support Center